Filing Flows › Biotricity (BTCY) › Q1 FY27 › vs Q4 FY26
Biotricity (BTCY) Q1 FY27 vs Q4 FY26 (quarter over quarter)
Biotricity's revenue rose $26K (+0.6%) from $4.3M in Q4 FY26 to $4.3M in Q1 FY27. The biggest changes: Technology Fees +$245K (+6%); Device Sales −$219K (-66%).
Biotricity, Q1 FY27: revenue $4.3M (+10% year over year), operating margin 3.7%, net loss $959K, operating cash flow $507K. The chart draws each line against Q4 FY26, the increases inside each band.
Every line
| Line | Q1 FY27 | Q4 FY26 | Change | % |
|---|---|---|---|---|
| Technology Fees | $4.2M | $3.9M | $245K | +6% |
| Device Sales | $111K | $329K | −$219K | -66% |
| Revenue | $4.3M | $4.3M | $26K | +0.6% |
| Net loss | $959K | $324K | $635K | +196% |
| Costs & expenses | $5.2M | $4.6M | $662K | +14% |
| Operating costs | $4.1M | $3.6M | $563K | +16% |
| Interest & other, net | $1.1M | $1.0M | $99K | +10% |
| Cost of revenue | $746K | $852K | −$105K | -12% |
| Research & development | $673K | $842K | −$168K | -20% |
| SG&A | $2.7M | $1.9M | $837K | +45% |
| Operating cash sources | $1.5M | $303K | $1.2M | +384% |
| Depreciation | $1K | $1K | $0 | 0% |
| Share-based compensation | $340K | $8K | $332K | 44× |
| Working capital & other | $1.1M | $294K | $831K | +283% |
| Net loss absorbed | $959K | $324K | $635K | +196% |
| Operating cash flow | $507K | −$21K | $528K | — |
Questions
How much did Biotricity's revenue grow quarter over quarter in Q1 FY27?
Biotricity's revenue rose $26K (+0.6%) from $4.3M in Q4 FY26 to $4.3M in Q1 FY27.
What drove Biotricity's revenue change in Q1 FY27?
Technology Fees +$245K (+6%); Device Sales −$219K (-66%).